Dr. Neelapu on Updated ZUMA-1 Findings in Non-Hodgkin Lymphoma

Sattva Neelapu, MD, associate professor, Department of Lymphoma/Myeloma, Division of Cancer Medicine, at The University of Texas MD Anderson Cancer Center, discusses the updated findings of the ZUMA-1 trial investigating axicabtagene ciloleucel (axi-cel; Yescarta) for patients with refractory aggressive non-Hodgkin lymphoma.

ZUMA-1 is a phase II multicenter trial of axicabtagene. which is a CD19-targeted chimeric antigen receptor (CAR) T-cell therapy, which enrolled 108 patients with refractory aggressive NHL, Neelapu explains. Eligible patients had no response to their last line or therapy, or they experienced relapse within 12 months after autologous stem cell transplant.

Results presented at the 2017 ASH Annual Meeting include a median follow-up of 15.4 months, with the best ORR of 82% and a best complete remission (CR) rate of 58%. Additionally, 40% patients remain in CR; in the ongoing cohort at 15.4 months, the ORR was 42%. The median overall survival and the median duration of response for the CR patients have not been reached. Currently, 56% of patients remain alive, he concludes.